
Allovir Inc (KLRS) Stock Forecast & Price Target
Allovir Inc (KLRS) Analyst Ratings
Bulls say
Kalaris Therapeutics Inc. demonstrates promising potential due to the novel features of its clinical-stage anti-VEGF drug, TH103, which exhibits superior retinal retention compared to existing therapies such as Eylea, suggesting extended durability for patients. The company benefits from the strong market performance of anti-VEGF treatments, as illustrated by Vabysmo surpassing $4 billion in global sales within its third year, indicating a significant opportunity for incremental advancements in this sector. Additionally, preclinical findings indicating complete inhibition of VEGF-induced endothelial cell proliferation provide a favorable outlook for TH103, positioning Kalaris Therapeutics to potentially capture market share in the growing field of retinal disease therapeutics.
Bears say
Kalaris Therapeutics Inc. faces significant financial challenges, as the company has yet to commercialize any products and is projected to continue incurring net losses until at least the early launch phase of its lead candidate, TH103. The competitive landscape poses additional risks, with existing and emerging therapies potentially hindering market penetration and affecting pricing strategies. Furthermore, the possibility of delays in clinical development and regulatory approvals could prolong the timeline and increase costs, compounding the financial risks for Kalaris.
This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.
Allovir Inc (KLRS) Analyst Forecast & Price Prediction
Start investing in Allovir Inc (KLRS)
Order type
Buy in
Order amount
Est. shares
0 shares